Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Year 2 Collaborative Project - UCSF and Battelle PNWD

Year 2 Collaborative Project - UCSF and Battelle PNWD

238
amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1 and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor , tissue necrosis factor , urokinase plasminogen activator, vascular endothelial growth factor
Proteomics
Breast and Gynecologic Cancers Research

To evaluate the effects of receptor status on circulating biomarker levels.

To analyze plasma levels of 24 proteins in 60 samples from women with either benign breast disease, or Her+ or ER+ cancers.
ELISA microarray

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 7/2/2018

The 33rd EDRN Steering Committee Meeting is from September 5-6, 2018 in Boston, MA. Please click here for meeting registration and hotel information.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.